Robert is a serial entrepreneur and executive with over 25 years of experience in the healthcare and life science industries. Most recently he was President and CEO of ViroCyt, Inc. ViroCyt was founded to develop and commercialize rapid virus quantification methods which can be used to accelerate development of new vaccines and gene therapy applications. The company’s products were quickly adopted by leading pharmaceutical and biotech companies and ViroCyt was acquired by Sartorius AG in July 2016. Previously Robert was the Founder, President and CEO of Medivance, Inc., which he built into the worldwide leader in therapeutic hypothermia treatment for critically ill patients. Medivance was acquired by CR Bard in 2011 for $260M and Robert was named Entrepreneur of the Year for the Mountain/Desert Region by Ernst and Young. Prior to Medivance, Robert held senior management positions at Pfizer and Covidien. Robert earned a MBA from the University of Colorado, a MS in Microbiology from the University of Illinois and a BA in chemistry from Colorado College.